Interruption or discontinuation of tyrosine kinase inhibitor treatment in chronic myeloid leukaemia: a retrospective cohort study (SPARKLE) in Belgium
T Devos, G Verhoef, E Steel, D Mazure, P Lewalle… - Acta …, 2019 - karger.com
Objectives: To assess interruptions/discontinuations of tyrosine kinase inhibitor (TKI)
treatment in Belgian patients with chronic myeloid leukaemia (CML). Methods: This …
treatment in Belgian patients with chronic myeloid leukaemia (CML). Methods: This …
[HTML][HTML] Successful planned pregnancy through vitrified-warmed embryo transfer in a woman with chronic myeloid leukemia: case report and literature review
Y Furukawa, T Takahashi, R Suganuma… - … of Hematology and …, 2020 - ncbi.nlm.nih.gov
A 35-year-old female patient with chronic myeloid leukemia (CML) wanted to have a child.
She had been treated with imatinib and had achieved major molecular remission, after …
She had been treated with imatinib and had achieved major molecular remission, after …
[HTML][HTML] Advantages of digital PCR in the detection of low abundance BCR‑ABL1 gene in patients with chronic myeloid leukemia
Z Yan, Q Sun, H Zhang, Y Han, J Qiao… - Oncology …, 2019 - spandidos-publications.com
Quantitative monitoring of BCR‑ABL1IS gene using reverse transcription quantitative‑PCR
(RT‑qPCR) is an important method for evaluating the treatment effects in patients with …
(RT‑qPCR) is an important method for evaluating the treatment effects in patients with …
Economic evaluations of tyrosine kinase inhibitors for patients with chronic myeloid leukemia in middle-and high-income countries: a systematic review
J Fu, Y Liu, H Lin, B Wu - Clinical Drug Investigation, 2018 - Springer
Objectives The objective of this systematic review was to conduct a comprehensive
assessment of economic evaluations of tyrosine kinase inhibitors (TKIs) in patients with …
assessment of economic evaluations of tyrosine kinase inhibitors (TKIs) in patients with …
[HTML][HTML] Promoter Hypermethylation of ATG16L2, TFAP2A, EBF2, Calcitonin, ABL1 Kinase Domain T315I Mutation Association with Imatinib Therapy Resistance and …
A Sarma, AC Kataki, AK Rai, M Hazarika… - Asian Pacific Journal of …, 2023 - waocp.com
Abstract Background and Objectives: Chronic myeloid leukemia (CML) initiation and
progression is regulated by epigenetic and genetic alterations. Imatinib therapy resistance in …
progression is regulated by epigenetic and genetic alterations. Imatinib therapy resistance in …
Real-life evaluation of potential candidates for treatment discontinuation in chronic myeloid leukemia: the impact of age and long-term follow-up
E Scalzulli, G Colafigli, S Pepe, G De Luca… - Leukemia & …, 2021 - Taylor & Francis
Discontinuation of tyrosine kinase inhibitors (TKIs) in chronic phase chronic myeloid
leukemia (CP-CML) patients has become a reality. Treatment-free remission (TFR) defines …
leukemia (CP-CML) patients has become a reality. Treatment-free remission (TFR) defines …
Treatment-free remission: a new therapeutic goal in chronic myelogenous leukemia
AG Elsayed, R Srivastava, MO Jamil - Current Oncology Reports, 2017 - Springer
Abstract Purpose of Review Chronic myelogenous leukemia (CML) is a chronic
myeloproliferative neoplasm characterized by the presence of Philadelphia chromosome [t …
myeloproliferative neoplasm characterized by the presence of Philadelphia chromosome [t …
Chronic myeloid leukemia (CML)
TG Knight, MR Grunwald, EA Copelan - Concise Guide to Hematology, 2019 - Springer
Chronic myeloid leukemia (CML) is a malignant disease of hematopoietic progenitor cells. It
arises from at (9; 22) which is a reciprocal chromosomal translocation between the ABL …
arises from at (9; 22) which is a reciprocal chromosomal translocation between the ABL …
[HTML][HTML] The BCL2L11 deletion polymorphism is not associated with imatinib resistance in chronic myeloid leukemia patients: meta-analysis
J Xu, J Gu, Y Zhao, H Meng, R Zhang, H Jiang, J Luo - Oncotarget, 2017 - ncbi.nlm.nih.gov
A common deletion polymorphism of the gene Bcl-2 like protein 11 (BCL2L11, BIM) has
been reported to cause tyrosine kinase inhibitors (TKIs) resistance in several malignant …
been reported to cause tyrosine kinase inhibitors (TKIs) resistance in several malignant …
Controversies regarding use of myeloid growth factors in leukemia
JN Poston, PS Becker - Journal of the National Comprehensive Cancer …, 2017 - jnccn.org
This review focuses on the data supporting the use of myeloid growth factors (MGFs) in
patients being treated for acute myeloid leukemia, acute lymphoblastic leukemia, chronic …
patients being treated for acute myeloid leukemia, acute lymphoblastic leukemia, chronic …